Transglutaminase inhibition ameliorates experimental diabetic nephropathy


Diabetic nephropathy is characterized by excessive extracellular matrix accumulation resulting in renal scarring and end-stage renal disease. Previous studies have suggested that transglutaminase type 2, by formation of its protein crosslink product epsilon-(gamma-glutamyl)lysine, alters extracellular matrix homeostasis, causing basement membrane thickening and expansion of the mesangium and interstitium. To determine whether transglutaminase inhibition can slow the progression of chronic experimental diabetic nephropathy over an extended treatment period, the inhibitor NTU281 was given to uninephrectomized streptozotocin-induced diabetic rats for up to 8 months. Effective transglutaminase inhibition significantly reversed the increased serum creatinine and albuminuria in the diabetic rats. These improvements were accompanied by a fivefold decrease in glomerulosclerosis and a sixfold reduction in tubulointerstitial scarring. This was associated with reductions in collagen IV accumulation by 4 months, along with reductions in collagens I and III by 8 months. This inhibition also decreased the number of myofibroblasts, suggesting that tissue transglutaminase may play a role in myofibroblast transformation. Our study suggests that transglutaminase inhibition ameliorates the progression of experimental diabetic nephropathy and can be considered for clinical application.

Publication DOI:
Divisions: College of Health & Life Sciences > School of Biosciences
College of Health & Life Sciences
College of Health & Life Sciences > Chronic and Communicable Conditions
College of Health & Life Sciences > School of Biosciences > Cellular and Molecular Biomedicine
Aston University (General)
Uncontrolled Keywords: diabetic nephropathy,extracellular matrix accumulation,renal scarring,end-stage renal diseas,transglutaminase type 2,protein crosslink product,ε-(γ-glutamyl)lysine,extracellular matrix homeostasis,basement membrane thickening,mesangium,interstitium,transglutaminase inhibition,chronic experimental diabetic nephropathy,treatment period,inhibitor NTU281,uninephrectomized streptozotocin-induced diabete,experimental diabetic nephropathy,clinical application,Nephrology
Publication ISSN: 1523-1755
Last Modified: 04 Jul 2024 07:01
Date Deposited: 11 Mar 2019 17:54
Full Text Link: http://www.natu ... ki2009230a.html
Related URLs: http://www.scop ... tnerID=8YFLogxK (Scopus URL)
PURE Output Type: Article
Published Date: 2009-08
Authors: Huang, Linghong
Haylor, John L.
Hau, Zoe
Jones, Richard A.
Vickers, Melissa E.
Wagner, Bart
Griffin, Martin (ORCID Profile 0000-0003-3824-306X)
Saint, Robert E.
Coutts, Ian G.C.
El Nahas, A. Meguid
Johnson, Timothy S.


Export / Share Citation


Additional statistics for this record